| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ART.23059 |
| P698 | PubMed publication ID | 18050221 |
| P50 | author | Paul Emery | Q19859634 |
| Gianfranco Ferraccioli | Q41067658 | ||
| Ronald van Vollenhoven | Q47265013 | ||
| Maxime Dougados | Q63136268 | ||
| P2093 | author name string | Edward Keystone | |
| Fabio Magrini | |||
| Roy Fleischmann | |||
| Simon Cooper | |||
| Sunil Agarwal | |||
| Joan Bathon | |||
| Daniel E. Furst | |||
| James Udell | |||
| Andrew Baldassare | |||
| Andrew Chubick | |||
| Matthew W. Cravets | |||
| P2860 | cites work | Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma | Q41505579 |
| P433 | issue | 12 | |
| P921 | main subject | immunology | Q101929 |
| patient | Q181600 | ||
| rheumatoid arthritis | Q187255 | ||
| rheumatology | Q327657 | ||
| rituximab | Q412323 | ||
| P304 | page(s) | 3896-3908 | |
| P577 | publication date | 2007-12-01 | |
| P1433 | published in | Arthritis and Rheumatism | Q23929027 |
| P1476 | title | Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis | |
| P478 | volume | 56 |
| Q38181132 | A Case of an Acquired Factor VIII Inhibitor Complicated by Multiple Treatment-Related Opportunistic Infections and Review of the Literature |
| Q97081764 | A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis |
| Q46007579 | Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients. |
| Q21093257 | Advances in rheumatology: new targeted therapeutics |
| Q24234197 | Adverse effects of biologics: a network meta-analysis and Cochrane overview |
| Q43451114 | Assessing infection risk with biologic agents in RA: methodological challenges |
| Q39811337 | B cell depletion for autoimmune diseases in paediatric patients |
| Q35903957 | B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases |
| Q37678888 | B cells in the pathogenesis and treatment of rheumatoid arthritis |
| Q44699204 | B-cell biology and related therapies in systemic lupus erythematosus |
| Q38192553 | Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae |
| Q37956137 | Cardiovascular safety of biologic therapies for the treatment of RA. |
| Q37270745 | Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis |
| Q36633769 | Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective. |
| Q26829810 | Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients |
| Q44358193 | Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. |
| Q35952231 | Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland |
| Q92147073 | Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis |
| Q35605474 | Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology |
| Q87424659 | Development of antirituximab antibodies in children with nephrotic syndrome |
| Q37754640 | Discussion: DMARDs and biologic therapies in the management of inflammatory joint diseases |
| Q33439180 | Disseminated intravascular coagulation-like reaction following rituximab infusion |
| Q38121632 | Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies. |
| Q37261621 | Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease. |
| Q38375767 | Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis. |
| Q34125254 | Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab' |
| Q34056237 | Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR) |
| Q33692751 | Experience with long-term rituximab use in a multiple sclerosis clinic |
| Q90513852 | Exploration and Evaluation of Therapeutic Efficacy of Drug-Free Macromolecular Therapeutics in Collagen-Induced Rheumatoid Arthritis Mouse Model |
| Q42261957 | Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome |
| Q42937261 | Good and bad memories following rituximab therapy |
| Q37385727 | Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice |
| Q37866813 | Immunological risk factors for infection after immunosuppressive and biologic therapies. |
| Q37358271 | Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature |
| Q39925216 | Indications of rituximab in autoimmune diseases |
| Q36245714 | Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity |
| Q37912944 | Infections associated with monoclonal antibody and fusion protein therapy in humans |
| Q37156636 | Infectious complications associated with monoclonal antibodies and related small molecules |
| Q30583310 | Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States |
| Q42229459 | Living life without B cells: is repeated B-cell depletion a safe and effective long-term treatment plan for rheumatoid arthritis? |
| Q57180421 | Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry |
| Q52642633 | Long-term persistence with rituximab in patients with rheumatoid arthritis. |
| Q41605329 | Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis |
| Q37130018 | Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients |
| Q60046431 | Low Percentage of Signal Regulatory Protein α/β Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients |
| Q35113679 | Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain |
| Q36338254 | Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment |
| Q84598859 | Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks? |
| Q58561333 | Nocebos in rheumatology: emerging concepts and their implications for clinical practice |
| Q38065768 | Overview of safety of non-biologic and biologic DMARDs |
| Q35557868 | Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study |
| Q38154934 | Preliminary analysis of mortality associated with rituximab use in autoimmune diseases |
| Q55481186 | Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. |
| Q36152477 | Prolonged B cell depletion with rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA). |
| Q44835064 | Rapid infusion with rituximab: short term safety in systemic autoimmune diseases. |
| Q34153073 | Rationale of using different biological therapies in rheumatoid arthritis |
| Q28238782 | Recent advances in the genetics of autoimmune disease |
| Q89835028 | Recurrent Campylobacter Enteritis in Patients with Hypogammaglobulinemia: Review of the Literature |
| Q35569500 | Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis |
| Q38085279 | Review on the influence of protocol design on clinical outcomes in rheumatoid arthritis treated with rituximab |
| Q57349151 | Rheumatoid arthritis |
| Q33757203 | Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab |
| Q40097140 | Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab. |
| Q64264101 | Rituximab Use in the Management of Childhood Nephrotic Syndrome |
| Q37690643 | Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis |
| Q43220265 | Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis |
| Q41859216 | Rituximab and cytokine release syndrome |
| Q38842494 | Rituximab and protection from vaccine preventable diseases: applying the evidence to pediatric patients. |
| Q24186568 | Rituximab for rheumatoid arthritis |
| Q27970312 | Rituximab for the treatment of IgG4-related orbital disease: experience from five cases |
| Q34500502 | Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis |
| Q37444678 | Rituximab for the treatment of rheumatoid arthritis: an update |
| Q28076091 | Rituximab in autoimmune diseases |
| Q45908921 | Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies. |
| Q37859111 | Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis |
| Q33765608 | Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients |
| Q38097748 | Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature |
| Q36434853 | Rituximab in the treatment of pemphigus vulgaris |
| Q42356161 | Rituximab off-label use for immune diseases: assessing adverse events in a single-centre drug-utilization survey |
| Q84962839 | Rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis |
| Q44493225 | Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients. |
| Q48669619 | Rituximab treatment in patients with refractory inflammatory myopathies |
| Q37781697 | Rituximab: a review of dermatological applications |
| Q36060036 | Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials |
| Q37944433 | Safety of biologic therapy in rheumatoid arthritis |
| Q38665700 | Safety profile of biological therapies for treating rheumatoid arthritis |
| Q55068903 | Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report. |
| Q55445399 | Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. |
| Q38983259 | Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies |
| Q34622760 | Targeting the B Cell in Rheumatoid Arthritis |
| Q37302795 | Targeting the B cell in vasculitis |
| Q34346198 | The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies |
| Q37168037 | The Janus of lupus--benefits and risks with B-cell therapy |
| Q83143549 | The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab |
| Q33683956 | The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease |
| Q41008088 | The impact of Rituximab therapy on the chromosomes of patients with Rheumatoid arthritis |
| Q37852715 | The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis. |
| Q37633537 | Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists |
| Q50698191 | To switch or to change class-the biologic dilemma in rheumatoid arthritis. |
| Q37912214 | Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point? |
| Q43472409 | Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience |
| Q37607063 | Treatment of rheumatoid arthritis: state of the art 2009. |
| Q37302417 | Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis |
| Q55099672 | Unusual and Interesting Adverse Cutaneous Drug Reactions. |
| Q38993240 | Update on the use of rituximab for intractable rheumatoid arthritis. |
| Q27691388 | Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis |
| Q44862147 | Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series |
| Q28074148 | What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis? |
| Q46008070 | [Anti-CD20 therapy in rheumatoid arthritis]. |
| Q87498316 | [Recommendations for use of rituximab in patients with rheumatoid arthritis] |
| Q44934331 | [Rituximab]. |
| Q28080246 | Rituximab for Rheumatoid Arthritis. |
Search more.